Objectives: A validated microbiological assay was used to measure concentrations of iclaprim (AR-100) in plasma, bronchial mucosa (BM), alveolar macrophages (AM) and epithelial lining fluid (ELF) after a single 1.6 mg/kg intravenous 60 min iv infusion of iclaprim.
Introduction
Iclaprim (AR-100) is a novel diaminopyrimidine and could be considered as a member of a new generation of dihydrofolate reductase inhibitors, which include trimethoprim. Iclaprim exhibits potent in vivo activity against Gram-positive (including methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae) and Gram-negative organisms. 1 Following single intravenous administration, the C max and AUC of iclaprim increased proportionally with dose, the t 1/2 (2 -4 h) and clearance were independent of dose; plasma protein binding of iclaprim in vitro was 92% to 94% over a wide range of concentrations. 2 Moreover, iclaprim has been shown to be active against organisms resistant to trimethoprim. In the treatment of respiratory infection, it is important that adequate concentrations of drug be achieved at potential sites of infection of the respiratory tree. 3 The aim of this study was to measure concentrations of iclaprim in plasma and compartments of the respiratory tree at three time intervals after a single 1.6 mg/kg intravenous infusion.
Materials and methods

Subjects
Twenty-four healthy men were enrolled into the study (mean age 25.3 years, range 19-39 years; mean weight 72.8 kg, range 58.8-87.4 kg), at Hammersmith Medicines Research at the Central Middlesex Hospital in London, UK. The Brent Medical Ethics Committee approved the study, and all subjects gave written informed consent. All subjects were screened within 21 days before bronchoscopy: screening included a detailed medical history, physical examination, blood samples for haematological and biochemical analysis, urinalysis and 12-lead ECG.
Dosing with iclaprim
Each subject received a single dose of 1.6 mg/kg iclaprim in 150 mL normal saline, given as an iv infusion over 60 min.
Sampling times
The times (acceptable ranges) between the start of the iclaprim infusion and the start of bronchoalveolar lavage (BAL) in Groups A, B and C were 1.5 (1-2), 3 (3-4), and 6 (5.5-6.5) h, respectively.
Sample collection
Bronchoscopy samples were collected as previously described. 4 Briefly, using standard procedures 5 bronchial mucosa (BM) and BAL were taken during bronchoscopy. For BAL collection, 200 mL of pre-warmed 0.9% saline was divided into four 50 mL aliquots. The aspirate from the first aliquot was discarded to avoid contamination of the sample with proximal airway fluid and cells; the remainder was pooled for analysis.
Microbiological assay
The microbiological assay was a modification of the method described by Allen and Nimmo-Smith. 6 Bacillus pumilis (NCTC 8241) spore suspension (spore count 7 Â 10 7 cfu/mL) 125 mL was added to 150 mL of Iso-Sensitest agar (Oxoid, Basingstoke, UK) and then poured into an assay plate (Mast Diagnostics, Bootle, UK). Antibiotic calibrators were prepared in pooled human serum (range 0.02 -0.64 mg/L), pH 7 phosphate buffer (range 0.02-0.32 mg/L), 0.9% NaCl (range 0.02-0.32 mg/L) and 9% NaCl (range 0.02-0.32 mg/L). Internal control samples (0.5, 0.2, 0.06 and 0.03 mg/L for human serum and 0.2 and 0.03 mg/L for pH 7 buffer, 0.9% and 9% NaCl) and quality assurance samples (range 0.048-0.64 mg/L for human serum, 0.024-0.29 mg/L for pH 7 buffer and 0.028-0.27 mg/L for 0.9% and 9% NaCl) were included on every assay plate. Holes of diameter 5 mm were punched into the agar, and calibrators, tests, control and quality assurance samples were applied in triplicate to the plate. Before incubation, the agar was exposed to ultraviolet light for 10 min to destroy surface growth of organism. After overnight incubation at 378C, zones were measured using an image analyser pre-programmed with Bennet's calculation 7 (Imaging associates, Thame, UK).
Calculation of iclaprim concentrations in epithelial lining fluid (ELF), alveolar macrophages (AM) and BM
Concentrations of antibiotic were calculated using the following formulae:
Bronchial mucosa
where AC, assayed concentration (mg/L); VB, volume of buffer added to homogenize the sample (mL) and WS, weight of tissue (mg).
Epithelial lining fluid
The concentration of urea in BAL was determined using a modified Infinity Kit (Alpha Laboratories, Eastleigh, UK).
where ACL, assayed concentration in lavage (mg/L), UL, urea concentration in lavage (mmol/L) and BL, blood urea concentration (mmol/L).
Alveolar macrophages
Antibiotic concentration in AMs was determined using a mean cell volume of an alveolar macrophage of 2.48 mL/10 6 cells.
Results
The lower limit of quantification of the microbiological assay was 0.02 mg/L. For the internal controls prepared in human serum, pH 7 buffer and NaCl, 97%, 79% and 97%, respectively, were within +15% of the assigned concentration. Ninety-six per cent (143/148) of the quality assurance samples were within +15% of the nominal concentration. Control urea samples included with every batch of urea estimations were within +13.4% of the assigned concentration. The mean urea concentration in BAL for 22 subjects was 0.039 mmol/L (range ,0.01 -0.083 mmol/L), urea not being detected in BAL samples from subjects 24 and 22. In the absence of urea as an endogenous marker, these samples could not be evaluated for iclaprim concentrations (see calculation above). The mean macrophage count and bronchial weight were 1.1 Â 10 5 cells/mL (range 0.5-2.53 Â 10 5 cells/mL) and 9.4 mg (range 3.3-16.7 mg), respectively. Iclaprim was not detected in the 3.3 mg BM sample for subject 8. It is presumed that the small sample weight precluded the measurement of the drug. Unlike other agents that this group has studied, the drug could be measured in all but three of the BAL samples (subjects 20, 1002 and 1004, who underwent BAL at 6.30-6.40 h after start of iclaprim infusion) without the need for concentration by freeze-drying. Mean concentrations of iclaprim in plasma, BM, AM and ELF, respectively, for the three nominal time windows were for 1-2 h (Group A) 0. Table 1 .
Iclaprim infusion was well tolerated, as was the BAL procedure.
Discussion
Published studies that investigate the penetration of trimethoprim into the respiratory tree are few, and those found looked at concentrations in saliva, bronchial secretions and normal and pathological lung tissue. 8, 9 None has investigated concentrations in ELF, BM and AM.
Co-trimoxazole has in vitro activity against S. pneumoniae (MIC distribution for the population lacking a mechanism of resistance 0.12 -0.5 mg/L; in-house data), however the British Society for Antimicrobial Chemotherapy (BSAC), following the Committee on the Safety of Medicines recommendations, suggests that the combination should be used only in specific circumstances. 10 In contrast, trimethoprim MICs (MIC distribution for the population lacking a mechanism of resistance 4 -16 mg/L; in-house data) exceed the BSAC breakpoint of 0.5 mg/L 8 and S. pneumoniae are therefore deemed resistant. This study has demonstrated that iclaprim concentrations in plasma, ELF and AM exceed the iclaprim MICs for penicillinsusceptible S. pneumoniae (MIC 90 0.06 mg/L) for up to 7 h and that mean iclaprim concentrations in ELF exceed the iclaprim MICs observed for S. pneumoniae with penicillin-intermediate S. pneumoniae MIC 90 2 mg/L and penicillin-resistant S. pneumoniae MIC 90 4 mg/L, for up to 7 and 4 h, respectively. For Haemophilus influenzae (MIC 90 4 mg/L) and Moraxella catarrhalis (MIC 90 8 mg/L), mean iclaprim concentrations exceeded MICs for these organisms for 7 and 4 h after the start of infusion, respectively, in AM. Furthermore, the MIC 90 for methicillin-resistant Staphylococcus aureus of 0.12 mg/L 1 was exceeded at all sites for up to 7 h. We have shown a high penetration of iclaprim into AM that would suggest that this drug should exhibit efficacy against Chlamydia pneumoniae (MIC 90 0.5 mg/L).
These data suggest that iclaprim might be effective for the treatment of respiratory infections, including those caused by pneumococci with low susceptibility to penicillin.
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